SFDA Approves Neusoft Mammography CAD
This article was originally published in PharmAsia News
Chinese software provider Neusoft Medical System received China's State FDA certification for its proprietary mammary Computer-Aided Diagnosis (CAD) product. Industry observers note this shows local companies have the capacity to develop, manufacture and sell international-standard CAD devices designed for Asians. At present, only a few American and European countries can manufacture such sophisticated equipment. Moreover, the development of mammoCAD is based mainly on Western pathology databases, which differ from Asian characteristics and thus affect the latter's detection rate. To address this issue, Neusoft has worked with major breast cancer hospitals in Tianjin and Liaoning province to specifically tailor its product for the Asian market. (Click here for more - Chinese Language)
You may also be interested in...
The MHRA has been working all hours to ensure the standalone medtech UKCA mark works operationally and procedurally in the UK as of 1 January 2021.
Development Partners International, CDC Group and the European Bank for Reconstruction and Development have collaborated to create a “first of its kind, pan-African” generics platform built on the acquisition and combination of Egypt’s Adwia Pharmaceuticals and India’s Celon Laboratories. An initial $250m investment is to be followed by up to $500m in further funding.
Market Brief: Tissue-Engineered Wound Care Market Expected To Reach $1.9BN By 2024 Amid Rising Chronic Disease
The skin replacement market is led by three key players who have all been impacted by COVID-19, but the sector may see a quicker rebound than others as treatments cannot be deferred for a long time.